Growth Opportunities in Global Biotech Investment, 2024

Growth Opportunities in Global Biotech Investment, 2024

Big Biopharma Companies Disruptive Technologies and Portfolio Realignment Will Ensure the Growth Potential of Biotech Investments

RELEASE DATE
09-Apr-2024
REGION
North America
Deliverable Type
Market Research
Research Code: PFGA-01-00-00-00
SKU: HC_2024_657
AvailableYesPDF Download
$2,450.00
In stock
SKU
HC_2024_657
$2,450.00
DownloadLink
ENQUIRE NOW

Description

In this analysis, Frost & Sullivan provides critical insights into the biotech M&A and venture capital (VC) investment, highlighting the drivers, challenges, predictions, and major trends in the biotech segment. This analysis also identifies actionable growth opportunities for industry participants to leverage.

To understand the trend outlook for 2024 and beyond, this analysis assesses strategic and financial investments, mergers and acquisitions (M&A), VC investments, and private equity (PE) from 2019 to 2023. Frost & Sullivan has gathered the total numbers for the entire ecosystem. However, the analytics only include the biotech/biopharma deals not involving small-molecule assets. The scope of this analysis is global, with 2023 as its base year, and includes forecasts up to 2028.

This assessment does not include debt deals and open deals. The deal volumes and values can vary because the data comes from secondary sources. Similarly, definitions for biotech vary. While certain sources record an M&A deal on the announcement date, some record the milestones as the transaction goes through, and others record the total value after completing the transaction.

Author: Surbhi Gupta

Table of Contents

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on Global Biotech Investments

Market Scope and Segmentation

Definitions

Growth Drivers

Growth Restraints

The State of the Biotech Industry—Biologics Pipeline

State of the Biotech Industry—Biologics Industry Outlook

Biotech M&A Investment Outlook—2024

Biotech VC Investment Outlook—2024

Top 3 Predictions—2024

Top 3 Big Pharma Investment Strategies for Portfolio Remodeling

Emerging Biotech Companies Top Trends—Impact Summary

Emerging Biotech Companies Top Trends—Impact Summary (continued)

New Modalities Driving Precision Medicine Will Remain Attractive

Investors Prioritizing Cardiometabolism, Oncology, CNS, and Immunology

Biotech M&A Trends

Big Biopharma M&A Activity

Biotech M&A Analysis by Therapeutic Segment

Biotech M&A Analysis by Modality

Key Biopharma M&A Targets2024

Key Biopharma M&A Targets2024 (continued)

Biotech VC Financing Trend

Top VC Financing Deals

Biotech VC Deal Analysis by Funding Stage

Biotech VC Deal Analysis by Therapeutic Segment

Biotech VC Deal Analysis by Modality

Biotech VC Deal Analysis by Stage of Clinical Development

Google Ventures (United States)

ARCH Ventures (United States)

RA Capital (United States)

SamsaraBio Capital (United States)

OrbiMed (United States)

Alexandria (United States)

Growth Opportunity 1: Acquiring Rare Disease-focused Biopharma Companies

Growth Opportunity 1: Acquiring Rare Disease-focused Biopharma Companies (continued)

Growth Opportunity 2: Investing in Precision Medicine Platform Technology-based Biotech Companies

Growth Opportunity 2: Investing in Precision Medicine Platform Technology-based Biotech Companies (continued)

Growth Opportunity 3: Investing in Clinical-stage Chinese Biopharma Companies

Growth Opportunity 3: Investing in Clinical-stage Chinese Biopharma Companies (continued)

Best Practices Recognition

Frost Radar

Benefits and Impacts of Growth Opportunities

Next Steps

Take the Next Step

List of Exhibits

Legal Disclaimer

In this analysis, Frost & Sullivan provides critical insights into the biotech M&A and venture capital (VC) investment, highlighting the drivers, challenges, predictions, and major trends in the biotech segment. This analysis also identifies actionable growth opportunities for industry participants to leverage. To understand the trend outlook for 2024 and beyond, this analysis assesses strategic and financial investments, mergers and acquisitions (M&A), VC investments, and private equity (PE) from 2019 to 2023. Frost & Sullivan has gathered the total numbers for the entire ecosystem. However, the analytics only include the biotech/biopharma deals not involving small-molecule assets. The scope of this analysis is global, with 2023 as its base year, and includes forecasts up to 2028. This assessment does not include debt deals and open deals. The deal volumes and values can vary because the data comes from secondary sources. Similarly, definitions for biotech vary. While certain sources record an M&A deal on the announcement date, some record the milestones as the transaction goes through, and others record the total value after completing the transaction. Author: Surbhi Gupta
More Information
Deliverable Type Market Research
Author Surbhi Gupta
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number PFGA-01-00-00-00